Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line
RBX2660 Filing Before Year-End
The promise of microbiome-based therapeutics to treat a variety of diseases has become a hot topic and the first to get to market will be targeting Clostridioides difficile infection. Ferring and its subsidiary Rebiotix are in pole position.
